Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xantinon is an over-the-counter hepatoprotective and lipotropic drug indicated as an aid in the treatment of liver disorders, such as non-alcoholic fatty liver disease (hepatic steatosis) and metabolic hepatic disturbances. The formulation combines racemethionine (an essential sulfur-containing amino acid) and choline chloride (a quaternary ammonium salt and precursor to phosphatidylcholine and acetylcholine). Together, these components act as lipotropic agents and methyl donors in the one-carbon transmethylation pathway. They facilitate the synthesis of lipoproteins (such as VLDL), which are essential for mobilizing and transporting triglycerides out of the liver, thereby preventing and reducing hepatic fat accumulation. Additionally, they support intracellular antioxidant defenses, helping to mitigate oxidative stress and promote the recovery of damaged hepatocytes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on racemethionine + choline chloride.